Last updated: August 1, 2026
Stiefel Laboratories is no longer an independent pharmaceutical company. GSK acquired Stiefel in 2009 for approximately $3.6 billion, creating a prescription-dermatology platform with acne, psoriasis, rosacea, fungal infection and topical corticosteroid products.[1] The business remains strategically relevant through branded dermatology assets, but its competitive position is narrower than it was before the acquisition because several legacy products face generic competition and newer dermatology growth is concentrated among larger specialty-pharmaceutical companies.
Stiefel’s principal strengths are its dermatology heritage, established prescriber relationships, topical formulation experience and portfolio breadth. Its main weaknesses are limited disclosure of standalone financial performance, exposure to generic substitution, aging brands and competition from AbbVie, Amgen, UCB, Incyte, Galderma, Organon, Almirall and numerous generic manufacturers.
What is Stiefel Laboratories’ current market position?
Stiefel is best analyzed as a GSK-owned dermatology business rather than as a standalone public company. GSK acquired the company after Stiefel had developed a broad prescription and consumer dermatology franchise, including Duac, Tazorac, Soriatane, Azelex, Veltin, Altabax and other topical products.[1]
GSK does not report Stiefel as a separate operating segment. Its public reporting combines products within broader pharmaceutical categories, and it does not provide standalone Stiefel revenue, EBITDA or market share. That limits direct valuation of the franchise.
Stiefel’s competitive position by therapeutic segment
| Segment |
Stiefel-linked products |
Primary competitors |
Competitive assessment |
| Acne |
Duac, Tazorac, Veltin, Fabior, generic clindamycin and retinoid products |
Galderma, Almirall, Bausch Health, Teva, Perrigo |
Mature market with strong generic pressure |
| Psoriasis |
Sorilux, Soriatane, Duobrii |
AbbVie, Amgen, UCB, Bristol Myers Squibb, Incyte |
Systemic biologics and newer topicals have raised the competitive standard |
| Atopic dermatitis |
Historical topical products and corticosteroid assets |
Sanofi/Regeneron, Pfizer, Incyte, LEO Pharma |
Stiefel has a weaker position in modern nonsteroidal therapy |
| Rosacea |
Historical topical and antibiotic products |
Galderma, Sol-Gel, generic manufacturers |
Established category, but differentiation depends on delivery and tolerability |
| Bacterial skin infection |
Altabax |
Generic mupirocin and other topical antibiotics |
Narrow opportunity with significant price competition |
| Fungal infection |
Historical Stiefel antifungal products |
Organon, Viatris, Teva, generic manufacturers |
Primarily a mature, genericized market |
The strongest strategic fit is prescription topical dermatology. Stiefel’s historical advantage came from formulation development, clinical familiarity and physician coverage rather than from a large biologics platform.
What products are associated with Stiefel Laboratories?
Stiefel’s portfolio has included several well-known prescription dermatology products. Product ownership, commercialization rights and geographic availability vary by country and may change through licensing or divestiture transactions.
| Product |
Active ingredient or technology |
Main indication |
FDA status and commercial issue |
| Duobrii |
Halobetasol propionate and tazarotene lotion |
Plaque psoriasis |
FDA-approved branded combination; faces competition from generic single-agent products and other topical combinations |
| Tazorac |
Tazarotene |
Acne vulgaris and plaque psoriasis |
Mature retinoid franchise with generic competition |
| Fabior |
Tazarotene foam |
Acne vulgaris |
Formulation differentiation, but limited market exclusivity relative to newer products |
| Sorilux |
Calcipotriene foam |
Plaque psoriasis |
Topical psoriasis product competing with generics and newer branded therapies |
| Soriatane |
Acitretin |
Severe psoriasis |
Oral retinoid with long-established clinical use and generic competition |
| Altabax |
Retapamulin ointment |
Impetigo |
Antibiotic product competing with mupirocin and other topical treatments |
| Duac |
Clindamycin and benzoyl peroxide |
Acne vulgaris |
Combination acne product exposed to generic substitution |
| Veltin |
Clindamycin and tretinoin |
Acne vulgaris |
Combination retinoid and antibiotic product in a crowded generic market |
GSK’s 2009 acquisition announcement described Stiefel as the world’s largest independent dermatology company at the time, with more than 15 marketed products and a pipeline of dermatology candidates.[1] The portfolio has since matured, and the market has shifted toward biologics, oral immunomodulators and differentiated topical delivery systems.
What patents protect Stiefel dermatology products?
Stiefel products are protected by product, formulation, method-of-use and manufacturing patents, but the relevant patent estate differs by product and jurisdiction. The most important U.S. protection is generally found in FDA Orange Book listings for approved small-molecule products.
Patent protection for Duobrii
Duobrii is a fixed-dose topical combination of halobetasol propionate and tazarotene. The FDA approved Duobrii lotion in November 2018 for plaque psoriasis in adults.[2]
Its commercial protection depends on:
- Composition and concentration claims covering the combination.
- Lotion formulation and vehicle claims.
- Methods of treating plaque psoriasis.
- Manufacturing and stability claims.
- Regulatory exclusivity and listed patent protections under the Hatch-Waxman framework.
The combination has a stronger differentiation profile than generic halobetasol or generic tazarotene alone because it combines a corticosteroid with a retinoid in a single vehicle. That advantage is commercially meaningful only if the formulation claims withstand invalidity and non-infringement challenges.
Patent protection for Tazorac and Fabior
Tazorac and Fabior rely on tazarotene formulation and dosage-form differentiation. Their original compound and early formulation patents are mature, and generic tazarotene products have entered the U.S. market.
The remaining commercial value lies in:
- Foam or lotion delivery.
- Vehicle composition.
- Dosing and administration methods.
- Specific indication claims.
- Barriers to substituting a generic cream or gel for a branded foam or lotion.
Generic approval does not always create automatic therapeutic equivalence across dosage forms. FDA product-specific guidance, formulation differences and state substitution rules can affect the speed and extent of generic erosion.[3]
Patent protection for Sorilux and other topical products
Sorilux uses a foam formulation of calcipotriene. Its principal differentiation is delivery technology and patient usability rather than a novel active pharmaceutical ingredient. Products of this type can retain commercial value after basic composition patents expire if the formulation is difficult to replicate or if physicians and patients prefer the branded dosage form.
That protection is weaker than a patent estate based on a new chemical entity. Generic manufacturers can challenge formulation claims, develop alternative vehicles or enter after approval through an abbreviated new drug application.
When do Stiefel products lose exclusivity?
Stiefel does not have a single company-wide patent expiration date. Each product has its own patent and regulatory-exclusivity timeline.
| Product |
Key exclusivity profile |
Generic-entry risk |
| Tazorac |
Legacy retinoid product with expired core exclusivity |
High |
| Fabior |
Formulation and dosage-form protection |
Medium to high |
| Sorilux |
Foam formulation protection and regulatory history |
Medium to high |
| Soriatane |
Mature oral retinoid with generic alternatives |
High |
| Altabax |
Legacy topical antibiotic franchise |
High |
| Duac and Veltin |
Combination-product protection largely mature |
High |
| Duobrii |
Newer branded combination approved in 2018 |
Medium, depending on Orange Book patent challenges and settlement outcomes |
The FDA Orange Book is the controlling reference for currently listed U.S. patents and pediatric exclusivity. Patent status can change through expiration, delisting, litigation, disclaimer, terminal disclaimer or settlement.[4]
What is the Orange Book status of Stiefel products?
Orange Book status must be evaluated at the product level. The relevant questions are:
- Which patents does the NDA holder list?
- Which claims cover the active ingredient, formulation or method of use?
- Are the patents eligible for Paragraph IV certification?
- Has a generic applicant filed an ANDA with a Paragraph IV notice?
- Did the NDA holder sue within 45 days?
- Has FDA approval been stayed under Hatch-Waxman?
- Did the parties settle, and does the agreement include a licensed entry date?
For topical products, formulation patents are often more important than active-ingredient patents because many actives have been used for decades. The commercial dispute may therefore center on whether a generic vehicle is infringing, therapeutically equivalent or substitutable at the pharmacy level.
Which companies are challenging Stiefel products?
Stiefel’s products compete with both branded pharmaceutical companies and generic manufacturers. The largest competitive threats vary by category.
Acne competition
Galderma has a strong acne franchise through Epiduo and related products. Almirall competes through topical acne and dermatology products. Bausch Health, Teva, Perrigo and other generic companies compete on price across clindamycin, tretinoin, tazarotene and benzoyl peroxide products.
The market has moved toward fixed combinations that improve adherence and reduce the need for separate prescriptions. This puts pressure on older Stiefel products that do not offer a clear delivery or tolerability advantage.
Psoriasis competition
Psoriasis is the most commercially challenging category for legacy topical products. AbbVie’s Skyrizi, Amgen’s Otezla and Enbrel, UCB’s Bimzelx and Cimzia, Bristol Myers Squibb’s Sotyktu and Incyte’s topical and oral therapies compete across disease severity and treatment line.
Duobrii occupies a topical niche. It does not compete directly with biologics in severe disease, but it competes with newer topical products in mild-to-moderate disease and with step-therapy requirements imposed by payers.
Atopic dermatitis competition
Sanofi and Regeneron’s Dupixent changed treatment expectations in atopic dermatitis. Pfizer’s Cibinqo, Incyte’s Opzelura and other systemic or topical immunomodulators offer alternatives to older corticosteroid-centered treatment.
Stiefel’s historical strengths are less differentiated in this segment. A competitive resurgence would require nonsteroidal mechanisms, superior topical delivery, improved safety or a targeted licensing strategy.
Which companies could file Paragraph IV challenges?
Generic companies with topical-development capabilities, including Teva, Perrigo, Viatris, Taro, Sandoz and specialized dermatology manufacturers, can be potential challengers to Stiefel-linked products. A Paragraph IV filing could target:
- A formulation patent.
- A method-of-use patent.
- A combination-product patent.
- A polymorph or particle-size claim.
- A manufacturing or stability claim.
For a topical drug, development risk is higher than for a simple oral tablet because the applicant may need to demonstrate pharmaceutical equivalence, comparable performance and, in some cases, complex product attributes. That can delay entry, but it does not eliminate the risk.
What patent litigation affects Stiefel products?
Patent litigation risk is concentrated in newer or commercially valuable formulations, particularly Duobrii and other topical dosage forms with Orange Book-listed patents. Legacy products such as Tazorac, Soriatane and Altabax face greater commercial erosion risk than litigation-driven uncertainty because generic products are already established.
A complete litigation assessment requires reviewing:
- ANDA litigation complaints.
- District court docket activity.
- Federal Circuit appeals.
- FDA Paragraph IV notices.
- Patent-term adjustments.
- Pediatric exclusivity.
- Settlement and license terms.
- Authorized-generic arrangements.
GSK’s public disclosures do not identify Stiefel as a separately reported litigation portfolio. Material disputes are generally reported within GSK’s broader legal-risk disclosures rather than under a standalone Stiefel heading.[5]
How strong is the Stiefel patent estate?
Stiefel’s patent estate is mixed.
| Patent dimension |
Assessment |
| New chemical entities |
Weak; most principal products use mature actives |
| Formulation patents |
Moderate; important for foams, lotions and fixed combinations |
| Method-of-use patents |
Moderate; value depends on claim scope and enforceability |
| Manufacturing patents |
Potentially useful but difficult to monetize independently |
| Regulatory exclusivity |
Strongest for newer approvals, including Duobrii |
| Generic barriers |
Moderate for complex topical formulations; low for mature simple products |
| Geographic coverage |
Uneven; U.S. protection is generally more visible than non-U.S. rights |
The estate is stronger as a portfolio of formulation and commercial dermatology assets than as a classic innovative-pharma patent platform. Its durability depends on lifecycle management, brand retention and the ability to defend topical formulation claims.
What FDA regulatory status applies to Stiefel products?
Stiefel products are generally FDA-approved prescription medicines regulated under the New Drug Application or Abbreviated New Drug Application pathways. The FDA approved Duobrii in 2018 for plaque psoriasis, while other products have older approval histories and may have transitioned into heavily genericized categories.[2]
FDA regulatory considerations include:
- Whether the product has an active NDA.
- Whether the dosage form has an approved generic equivalent.
- Whether a generic is therapeutically equivalent and substitutable.
- Whether FDA has issued product-specific guidance.
- Whether the product carries boxed warnings or significant labeling restrictions.
- Whether a supplemental NDA supports a new indication or delivery system.
Topical corticosteroids and retinoids also carry safety and tolerability considerations that influence labeling, payer coverage and physician adoption.
Does Stiefel face biosimilar risk?
Direct biosimilar risk is limited because Stiefel’s principal products are small-molecule drugs and topical formulations, not biologics. FDA biosimilar competition affects competing dermatology products such as biologic therapies for psoriasis and atopic dermatitis, not the Stiefel portfolio directly.
The indirect risk is substantial. Biosimilar entry can reduce the price of biologic treatment and make systemic therapy more accessible. That may increase payer pressure on branded topical products and reduce the relative value of older topical therapies in treatment algorithms.
What licensing deals and partnerships affect Stiefel?
The acquisition by GSK remains the central transaction shaping Stiefel’s ownership and commercial strategy. GSK purchased Stiefel for approximately $3.6 billion in 2009, including assumed debt, according to GSK’s announcement.[1]
Stiefel’s strategic model historically relied on:
- Internal topical formulation development.
- Dermatology-focused sales infrastructure.
- Product acquisitions and licensing.
- Lifecycle management through new dosage forms.
- Geographic commercialization partnerships.
GSK’s public financial reporting does not provide a complete, current list of every license, regional commercialization arrangement or product-rights transfer associated with the Stiefel portfolio. Rights may differ between the United States, Europe, Canada, Latin America and emerging markets.
What revenue exposure does GSK have to Stiefel?
GSK does not disclose standalone Stiefel revenue. The absence of segment reporting prevents a precise calculation of GSK’s exposure to individual Stiefel products.
Revenue exposure is likely concentrated in products with:
- Current branded reimbursement.
- Limited therapeutic substitution.
- Formulation or combination differentiation.
- Strong dermatology-prescriber recognition.
- Higher barriers to generic development.
Legacy products with established generic equivalents have lower strategic value and lower margin protection. Duobrii is more relevant to current branded revenue because it entered the market later and uses a differentiated fixed-combination lotion. Its value remains sensitive to payer restrictions, competing topical products and patent challenges.
How does Stiefel compare with leading dermatology companies?
| Company |
Core strength |
Competitive advantage versus Stiefel |
| AbbVie |
Psoriasis and immunology biologics |
Scale, biologic depth and payer influence |
| Sanofi/Regeneron |
Atopic dermatitis and immunology |
Dupixent franchise and clinical leadership |
| Galderma |
Aesthetic and medical dermatology |
Broad dermatology focus and consumer reach |
| Incyte |
Topical and oral immunology |
Newer mechanisms and differentiated products |
| Almirall |
Medical dermatology |
Focused specialty portfolio and regional depth |
| Organon |
Mature women’s health and dermatology assets |
Generic and established-brand infrastructure |
| Stiefel/GSK |
Topical prescription dermatology |
Heritage, formulation expertise and installed physician relationships |
Stiefel is strongest against smaller topical competitors and weakest against companies with biologics, novel immunology mechanisms or large specialty sales forces.
What generic launch scenarios exist for Stiefel products?
Scenario one: Immediate erosion
A generic equivalent launches after patent expiration or a successful invalidity decision. Pharmacy substitution drives rapid price and volume erosion, particularly for mature topical products.
Scenario two: Delayed launch
A generic applicant receives approval but delays commercial entry because of litigation, settlement terms, manufacturing constraints or a negotiated license date.
Scenario three: Partial substitution
A generic enters in a different vehicle or dosage form but does not substitute automatically for the branded product. The brand retains a smaller premium segment based on physician preference, patient response or payer policy.
Scenario four: Authorized generic competition
The brand owner licenses or launches an authorized generic to capture value after patent expiry. This can protect volume but usually reduces the branded product’s net price.
What geographic coverage does Stiefel have?
Stiefel historically operated internationally, and GSK’s acquisition expanded the company’s global dermatology platform. Patent and regulatory coverage varies by territory. A U.S. patent position does not establish equivalent protection in the European Union, Japan, China, Canada, Australia or Latin America.
Key geographic variables include:
- National patent term and supplementary protection rights.
- Local Orange Book equivalents.
- Data and market exclusivity.
- National reimbursement systems.
- Pharmacy substitution rules.
- Local manufacturing and import requirements.
- Regional licensees and distributors.
The United States remains the most important market for Paragraph IV and Orange Book analysis. European and emerging-market value depends more heavily on national reimbursement, local registration and commercial execution.
What manufacturing and intellectual-property barriers protect Stiefel?
Topical products can have meaningful manufacturing barriers even when their active ingredients are old. Relevant barriers include:
- Emulsion and suspension control.
- Particle-size distribution.
- Uniformity of active ingredients.
- Vehicle rheology.
- Preservative systems.
- Container-closure compatibility.
- Stability under temperature variation.
- Scale-up reproducibility.
- Dermal delivery and permeation performance.
These barriers support formulation patents and may increase the cost of generic development. They do not guarantee long-term exclusivity. A competitor can avoid infringement by using a different vehicle or manufacturing process while pursuing FDA approval.
Key Takeaways
- Stiefel is a GSK-owned dermatology platform, not an independent company.
- GSK acquired Stiefel in 2009 for approximately $3.6 billion.
- The portfolio is concentrated in topical dermatology, acne, psoriasis and mature prescription products.
- Duobrii is the most strategically differentiated current product because of its halobetasol-tazarotene fixed-combination lotion.
- Tazorac, Fabior, Sorilux, Soriatane, Altabax, Duac and Veltin face substantial generic or mature-market pressure.
- Stiefel’s patent strength is concentrated in formulations, dosage forms and methods of use rather than new chemical entities.
- Biosimilar risk is indirect, but biologic competition can reduce the value of branded topical treatments.
- GSK does not disclose standalone Stiefel revenue, preventing a precise franchise valuation from public filings.
- The principal strategic options are formulation lifecycle management, selective dermatology licensing, authorized-generic planning and expansion into nonsteroidal or specialty dermatology treatments.
FAQs
Is Stiefel Laboratories still an independent company?
No. GSK acquired Stiefel Laboratories in 2009. Stiefel is analyzed as part of GSK’s dermatology operations.
Who owns Duobrii?
Duobrii is associated with GSK’s Stiefel dermatology business. The FDA approved the product in 2018 for plaque psoriasis in adults.
Are Stiefel dermatology products genericized?
Several legacy Stiefel products have generic competition. Generic exposure is highest for mature retinoid, antibiotic and corticosteroid products.
Does Stiefel have biologic dermatology products?
Stiefel’s established portfolio is primarily composed of small-molecule and topical products. Its direct biologic exposure is limited compared with AbbVie, Sanofi/Regeneron, Amgen and UCB.
Is Stiefel a major competitor to Galderma?
Stiefel competes with Galderma in prescription topical dermatology, particularly acne and other medical-dermatology categories. Galderma has broader scale across medical aesthetics, skincare and prescription dermatology.
References
- GlaxoSmithKline. (2009, April 22). GSK to acquire Stiefel Laboratories for $3.6 billion. https://www.gsk.com
- U.S. Food and Drug Administration. (2018, November 1). FDA approves Duobrii lotion for plaque psoriasis. https://www.fda.gov
- U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. https://www.fda.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov
- GSK plc. (2024). Annual report 2023. https://www.gsk.com
